Enrolled UCSF
64
Enrolled Oregon
232
Enrolled Michigan
733
Enrolled Mayo
129
| Characteristic | White N = 1,0071 |
Black or African American N = 491 |
Asian N = 291 |
Native Hawaiian or other Pacific Islander N = 01 |
American Indian or Alaskan Native N = 21 |
Middle Eastern or North African N = 81 |
Other N = 101 |
Unknown/not reported N = 171 |
Multiple N = 281 |
|---|---|---|---|---|---|---|---|---|---|
| Gender | |||||||||
| Cisgender Female | 516 (51%) | 27 (55%) | 11 (38%) | 0 (NA%) | 2 (100%) | 2 (25%) | 5 (50%) | 7 (41%) | 10 (36%) |
| Cisgender Male | 380 (38%) | 18 (37%) | 16 (55%) | 0 (NA%) | 0 (0%) | 6 (75%) | 4 (40%) | 8 (47%) | 12 (43%) |
| Transgender Female | 31 (3.1%) | 2 (4.1%) | 0 (0%) | 0 (NA%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5.9%) | 2 (7.1%) |
| Transgender Male | 32 (3.2%) | 1 (2.0%) | 1 (3.4%) | 0 (NA%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Gender Non-Binary (including genderqueer) | 44 (4.4%) | 1 (2.0%) | 1 (3.4%) | 0 (NA%) | 0 (0%) | 0 (0%) | 1 (10%) | 1 (5.9%) | 4 (14%) |
| Unknown/not reported | 4 (0.4%) | 0 (0%) | 0 (0%) | 0 (NA%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Ethnicity | |||||||||
| Hispanic | 25 (2.5%) | 1 (2.0%) | 1 (3.4%) | 0 (NA%) | 1 (50%) | 0 (0%) | 5 (50%) | 4 (24%) | 4 (14%) |
| Non-Hispanic | 964 (96%) | 47 (96%) | 26 (90%) | 0 (NA%) | 1 (50%) | 8 (100%) | 5 (50%) | 7 (41%) | 23 (82%) |
| Unknown/not reported | 18 (1.8%) | 1 (2.0%) | 2 (6.9%) | 0 (NA%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (35%) | 1 (3.6%) |
| IBD Type | |||||||||
| Crohn's disease | 577 (58%) | 35 (71%) | 12 (41%) | 0 (NA%) | 1 (50%) | 5 (63%) | 7 (70%) | 9 (53%) | 21 (75%) |
| Ulcerative colitis | 410 (41%) | 13 (27%) | 17 (59%) | 0 (NA%) | 1 (50%) | 3 (38%) | 3 (30%) | 8 (47%) | 7 (25%) |
| Indeterminate colitis | 14 (1.4%) | 0 (0%) | 0 (0%) | 0 (NA%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Other | 1 (<0.1%) | 1 (2.0%) | 0 (0%) | 0 (NA%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Unknown | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 n (%) | |||||||||
| Characteristic | Case (SGM) N = 8471 |
Control (non-SGM) N = 9471 |
|---|---|---|
| Drug | ||
| adalimumab | 191 (23%) | 226 (24%) |
| certolizumab | 32 (3.8%) | 32 (3.4%) |
| etrasimod | 1 (0.1%) | 0 (0%) |
| golimumab | 7 (0.8%) | 3 (0.3%) |
| infliximab | 260 (31%) | 289 (31%) |
| IVIG | 0 (0%) | 1 (0.1%) |
| natalizumab | 1 (0.1%) | 1 (0.1%) |
| ozanimod | 2 (0.2%) | 0 (0%) |
| risankizumab | 41 (4.8%) | 63 (6.7%) |
| tofacitinib | 11 (1.3%) | 26 (2.7%) |
| upadacitinib | 39 (4.6%) | 51 (5.4%) |
| ustekinumab | 127 (15%) | 137 (14%) |
| vedolizumab | 135 (16%) | 118 (12%) |
| 1 n (%) | ||
| Characteristic | Case (SGM) N = 5761 |
Control (non-SGM) N = 5821 |
|---|---|---|
| Site | ||
| Mayo Clinic | 106 (82%) | 23 (18%) |
| Oregon Health and Science University | 106 (46%) | 126 (54%) |
| University of California San Francisco | 37 (58%) | 27 (42%) |
| University of Michigan | 327 (45%) | 406 (55%) |
| 1 n (%) | ||
| Characteristic | Case (SGM) N = 5551 |
Control (non-SGM) N = 5791 |
p-value2 |
|---|---|---|---|
| Depression history? | 347 (80%) | 219 (64%) | <0.001 |
| Unknown | 120 | 239 | |
| Bipolar history? | 49 (11%) | 11 (3.2%) | <0.001 |
| Unknown | 120 | 239 | |
| Anxiety disorder? | 353 (81%) | 298 (88%) | 0.014 |
| Unknown | 120 | 239 | |
| Post Traumatic Stress Disorder (PTSD)? | 92 (21%) | 28 (8.2%) | <0.001 |
| Unknown | 120 | 239 | |
| 1 n (%) | |||
| 2 Pearson’s Chi-squared test | |||
| Characteristic | Case (SGM) N = 5541 |
Control (non-SGM) N = 5791 |
p-value2 |
|---|---|---|---|
| How many hospital admissions for IBD (excluding scheduled surgery) did the patient have in the most recent 12 months of follow up? | 0.054 | ||
| 0 | 473 (86%) | 468 (81%) | |
| 1 | 57 (10%) | 70 (12%) | |
| 2 | 15 (2.7%) | 18 (3.1%) | |
| 3 | 6 (1.1%) | 10 (1.7%) | |
| 4 | 0 (0%) | 5 (0.9%) | |
| 5 | 1 (0.2%) | 1 (0.2%) | |
| More than 5 | 1 (0.2%) | 7 (1.2%) | |
| Unknown | 1 | 0 | |
| How many ER visits without hospitalization for IBD (excluding scheduled surgery) did the patient have in the most recent 12 months of follow up? | >0.9 | ||
| 0 | 485 (88%) | 501 (87%) | |
| 1 | 49 (8.9%) | 56 (9.7%) | |
| 2 | 11 (2.0%) | 12 (2.1%) | |
| 3 | 5 (0.9%) | 5 (0.9%) | |
| 4 | 1 (0.2%) | 2 (0.3%) | |
| 5 | 0 (0%) | 1 (0.2%) | |
| More than 5 | 2 (0.4%) | 2 (0.3%) | |
| Unknown | 1 | 0 | |
| 1 n (%) | |||
| 2 Fisher’s exact test | |||
